Lv61
2040 积分 2024-02-02 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
12天前
已完结
Iopromide safety assessment in a radiology department: A seven-year retrospective characterization of adverse events
14天前
已完结
Effects of Low-Osmolar Contrast Media on Long-Term Renal Impairment After Coronary Angiography: Iohexol Versus Iopromide
14天前
已完结
Safety of non-ionic contrast media in CT examinations for out-patients: retrospective multicenter analysis of 473,482 patients
14天前
已完结
Anaphylactic risk associated with iodinated and gadolinium-based contrast media
15天前
已完结
Data Mining and Analysis for Iodinated Contrast Media Adverse Event Signals Based on the Food and Drug Administration Adverse Event Reporting System Database
15天前
已完结
Acute Adverse Events After Iodinated Contrast Agent Administration of 359,977 Injections: A Single-Center Retrospective Study
15天前
已完结
Post-mortem distribution of Iodinated Contrast Media (ICM) (iodixanol versus iopromide) in the porcine kidney after multiple bolus injections in vivo into the supra-renal aorta1
15天前
已完结
Hemodynamic effects of intravenous bolus injection of iopromide 370 twice in abdominal contrast-enhanced CT and coronary CTA dual-site sequential examinations
16天前
已完结
[Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma]
1个月前
已完结
皖公网安备34019202002308
